Display options
Cite
Kishimoto S, Ishihara M, Takikawa M, et al. Novel experimental and clinical therapeutic uses of low-molecular-weight heparin/protamine microparticles. Pharmaceutics. 2012;4(1):42-57doi: 10.3390/pharmaceutics4010042.
Kishimoto, S., Ishihara, M., Takikawa, M., Mori, Y., Hattori, H., Fujita, M., & Nakamura, S. (2012). Novel experimental and clinical therapeutic uses of low-molecular-weight heparin/protamine microparticles. Pharmaceutics, 4(1), 42-57. https://doi.org/10.3390/pharmaceutics4010042
Kishimoto, Satoko, et al. "Novel experimental and clinical therapeutic uses of low-molecular-weight heparin/protamine microparticles." Pharmaceutics vol. 4,1 (2012): 42-57. doi: https://doi.org/10.3390/pharmaceutics4010042
Kishimoto S, Ishihara M, Takikawa M, Mori Y, Hattori H, Fujita M, Nakamura S. Novel experimental and clinical therapeutic uses of low-molecular-weight heparin/protamine microparticles. Pharmaceutics. 2012 Jan 11;4(1):42-57. doi: 10.3390/pharmaceutics4010042. PMID: 24300179; PMCID: PMC3834902.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2012 Jan 11;4(1):42-57. doi: 10.3390/pharmaceutics4010042.

Novel experimental and clinical therapeutic uses of low-molecular-weight heparin/protamine microparticles.

Pharmaceutics

Satoko Kishimoto, Masayuki Ishihara, Megumi Takikawa, Yasutaka Mori, Hidemi Hattori, Masanori Fujita, Shingo Nakamura

Affiliations

  1. Research Institute, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan. [email protected].

PMID: 24300179 PMCID: PMC3834902 DOI: 10.3390/pharmaceutics4010042

Abstract

Low-molecular-weight heparin/protamine microparticles (LMW-H/P MPs) were produced as a carrier for heparin-binding growth factors (GFs) and for various adhesive cells. A mixture of low-molecular-weight heparin (MW: approximately 5000 Da, 6.4 mg/mL) and protamine (MW: approximately 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles (0.5-3 µm in diameter). LMW-H/P MPs immobilize, control the release and protect the activity of GFs. LMW-H/P MPs can also bind to cell surfaces, causing these cells to interact with the LMW-H/P MPs, inducing cells/MPs-aggregate formation and substantially promoting cellular viability. Furthermore, LMW-H/P MPs can efficiently bind to tissue culture plates and retain the binding of important GFs, such as fibroblast growth factor (FGF)-2. The LMW-H/P MPs-coated matrix with various GFs or cytokines may provide novel biomaterials that can control cellular activity such as growth and differentiation. Thus, LMW-H/P MPs are an excellent carrier for GFs and various cells and are an efficient coating matrix for cell cultures.

References

  1. Thromb Haemost. 1995 Mar;73(3):439-43 - PubMed
  2. J Biomed Mater Res A. 2009 Dec;91(3):814-23 - PubMed
  3. J Neurosci Res. 2002 Sep 15;69(6):908-17 - PubMed
  4. Mol Ther. 2004 May;9(5):747-56 - PubMed
  5. J Biomed Mater Res B Appl Biomater. 2011 May;97(2):373-80 - PubMed
  6. Science. 1998 Mar 6;279(5356):1528-30 - PubMed
  7. J Biomed Mater Res A. 2006 May;77(2):351-61 - PubMed
  8. J Atheroscler Thromb. 2006 Apr;13(2):77-81 - PubMed
  9. Chest. 2001 Jan;119(1 Suppl):64S-94S - PubMed
  10. J Vasc Surg. 2011 Sep;54(3):791-8 - PubMed
  11. Int J Nanomedicine. 2010 Apr 07;5:147-55 - PubMed
  12. Biomaterials. 2004 Feb;25(4):699-706 - PubMed
  13. Clin Exp Metastasis. 1990 Jul-Aug;8(4):381-9 - PubMed
  14. Blood. 2007 Aug 15;110(4):1317-25 - PubMed
  15. Nature. 1988 Mar 24;332(6162):376-8 - PubMed
  16. Nature. 1987 Mar 26-Apr 1;326(6111):403-5 - PubMed
  17. Implant Dent. 2001;10(4):225-8 - PubMed
  18. Blood. 1998 Dec 15;92(12):4641-51 - PubMed
  19. Artif Organs. 2009 Jun;33(6):431-8 - PubMed
  20. J Biomed Mater Res B Appl Biomater. 2006 Jan;76(1):230-9 - PubMed
  21. J Biomed Mater Res B Appl Biomater. 2011 Feb;96(2):234-41 - PubMed
  22. J Cell Physiol. 1986 Sep;128(3):475-84 - PubMed
  23. Science. 1997 Apr 4;276(5309):71-4 - PubMed
  24. Dermatol Surg. 2011 Dec;37(12):1721-9 - PubMed
  25. Tissue Eng Part C Methods. 2009 Sep;15(3):523-7 - PubMed
  26. Diabetologia. 2009 Sep;52(9):1971-3 - PubMed
  27. Thromb Res. 1994 Jul 1;75(1):1-32 - PubMed
  28. J Biomed Mater Res A. 2008 Jun 1;85(3):619-27 - PubMed
  29. J Surg Res. 2011 Sep;170(1):e189-96 - PubMed
  30. Science. 1999 Apr 2;284(5411):143-7 - PubMed
  31. J Control Release. 2009 Feb 10;133(3):185-90 - PubMed
  32. Tissue Eng. 2004 Jul-Aug;10(7-8):1054-64 - PubMed
  33. FASEB J. 1996 Sep;10(11):1270-9 - PubMed
  34. Facial Plast Surg. 2002 Feb;18(1):27-33 - PubMed
  35. J Biomed Mater Res A. 2010 Mar 15;92(4):1614-22 - PubMed
  36. Stem Cells. 2006 Jan;24(1):105-14 - PubMed
  37. J Biomed Mater Res. 2002 Mar 5;59(3):450-9 - PubMed
  38. Nat Med. 2005 Feb;11(2):228-32 - PubMed
  39. J Leukoc Biol. 1996 Mar;59(3):435-41 - PubMed
  40. Am J Cardiol. 1997 Nov 15;80(10):1336-8 - PubMed

Publication Types